RIPK1-IN-29

RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases[1].

Product Specifications

UNSPSC

12352005

Target

RIP kinase

Related Pathways

Apoptosis

Field of Research

Inflammation/Immunology

Smiles

O=S(N1OCC[C@H]1C2=CC=CC=C2)(CC3=CC=CC=C3)=O

Molecular Formula

C16H17NO3S

Molecular Weight

303.38

References & Citations

[1]Ma L, et al. Discovery of phenylisoxazolidine analogs targeting receptor interacting protein kinase 1 with anti-inflammatory activity. Eur J Med Chem. 2025 Jun 5;290:117530.